Interpace Biosciences, Inc. (OTCMKTS:IDXG) Sees Large Growth in Short Interest

Interpace Biosciences, Inc. (OTCMKTS:IDXG) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totaling 785 shares, a growth of 7,750.0% from the May 31st total of 10 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 11,418 shares, the days-to-cover ratio is currently 0.1 days.

Interpace Biosciences Price Performance

IDXG stock opened at $1.64 on Friday. Interpace Biosciences has a 1-year low of $0.70 and a 1-year high of $2.40. The business has a 50 day simple moving average of $1.83 and a two-hundred day simple moving average of $1.69. The company has a market capitalization of $7.27 million, a price-to-earnings ratio of -32.80 and a beta of 0.59.

Interpace Biosciences (OTCMKTS:IDXG) last released its earnings results on Tuesday, May 12th. The business services provider reported $0.03 EPS for the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%. The firm had revenue of $9.03 million for the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.